In Brief: FDA June "approvables"
FDA June "approvables": Janssen's Propulsid suspension (cisapride monohydrate) deemed "approvable" June 13. NDA 20-398 covers two strengths of the new formulation, 1 mg base/mL and 2 mg base/mL. The upper GI tract motility stimulator is approved in tablet form. On June 22, FDA grants "approvable" status to Boehringer Ingelheim's Atrovent (ipratropium bromide) .021 mg for symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis and .042 mg metered-dose spray for symptomatic relief of rhinorrhea associated with the common cold. Atrovent is currently indicated for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth